Please login to the form below

Not currently logged in
Email:
Password:

BMS hires Roche's Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

Mike Burgess, BMSMike Burgess has left Roche to become senior VP, discovery medicine and clinical pharmacology at Bristol-Myers Squibb.

Most recently, he was interim head of research and early development at Roche - a position now occupied by John Reed - and had previously led the Swiss pharma firm's oncology discovery and translational area at the same time as serving as head of global large molecule research.

In his new role, he will report to Dr Francis Cuss, senior VP research, R&D, and will be a member of BMS's research senior leadership team.

“As a physician scientist with a PhD in molecular biology, clinical experience in paediatrics and paediatric oncology, and extensive pharmaceutical industry and leadership experience, I believe Mike will be an important addition to our research and development organisation,” said Dr Cuss.

“Mike's broad clinical expertise, cross-therapeutic global team leadership and proven operational excellence will enable Bristol-Myers Squibb to continue to execute its strategy of ensuring sustainable delivery of an innovative pipeline of new medicines for patients.”

Prior to joining Roche, Dr Burgess was a medical fellow at Lilly, having completed his PhD at the University of Bristol in the UK.

21st January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics